Oncotarget

Research Papers:

Involvement of AF1q/MLLT11 in the progression of ovarian cancer

Paola Tiberio, Ludmila Lozneanu, Valentina Angeloni, Elena Cavadini, Patrizia Pinciroli, Maurizio Callari, Maria Luisa Carcangiu, Domenica Lorusso, Francesco Raspagliesi, Valentina Pala, Maria Grazia Daidone and Valentina Appierto _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:23246-23264. https://doi.org/10.18632/oncotarget.15574

Metrics: PDF 1112 views  |   HTML 1518 views  |   ?  


Abstract

Paola Tiberio1, Ludmila Lozneanu1,2, Valentina Angeloni1, Elena Cavadini1, Patrizia Pinciroli3, Maurizio Callari1,4, Maria Luisa Carcangiu5, Domenica Lorusso6, Francesco Raspagliesi6, Valentina Pala1, Maria Grazia Daidone1, Valentina Appierto1

1Department of Experimental Oncology and Molecular Medicine, Biomarkers Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

2Department of Morphofunctional Sciences–Histology, Patology, “Grigore T. Popa” University of Medicine and Pharmacy, Iassy, Romania

3Department of Experimental Oncology and Molecular Medicine, Functional Genomics Facility, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

4Present address: Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, United Kingdom

5Department of Pathology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

6Department of Surgery, Gynecologic Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Correspondence to:

Valentina Appierto, email: valentina.appierto@istitutotumori.mi.it

Keywords: AF1q/MLLT11, ovarian cancer, borderline ovarian tumor/BOT, low malignant potential ovarian tumor, EMT

Received: January 26, 2016     Accepted: February 12, 2017     Published: February 21, 2017

ABSTRACT

The functional role of AF1q/MLLT11, an oncogenic factor involved in a translocation t(1;11)(q21;q23) responsible for acute myeloid leukaemia, has been investigated in hematological and solid malignancies and its expression was found to be linked to tumor progression and poor clinical outcome. In addition to its oncogenic function, AF1q has been shown to play a role in the onset of basal and drug-induced apoptosis in cancer cells of different histotypes, including ovarian cancer. Through in vitro, ex vivo, and in silico approaches, we demonstrated here that AF1q is also endowed with protumorigenic potential in ovarian cancer. In ovarian cancer cell lines, stable AF1q overexpression caused activation of epithelial-to-mesenchymal transition and increased motility/migratory/invasive abilities accompanied by gene expression changes mainly related to Wnt signaling and to signaling pathways involving in ERK/p38 activation. The potential role of AF1q in ovarian cancer progression was confirmed by immunohistochemical and in silico analyses performed in ovarian tumor specimens which revealed that the protein was absent in normal ovarian epithelium and became detectable when atypical proliferation was present. Moreover, AF1q was significantly lower in borderline ovarian tumors (i.e., tumors of low malignant potential without stromal invasion) than in invasive tumors, thus corroborating the association between high AF1q expression and increased migratory/invasive cell behavior and confirming its potential role in ovarian cancer progression. Our findings demonstrated, for the first time, that AF1q is endowed with protumorigenic activity in ovarian cancer, thus highlighting a dual behavior (i.e., protumorigenic and proapoptotic functions) of the protein in the malignancy.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15574